Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder primarily affecting motor neurons. Mutations in optineurin cause a proportion of familial ALS cases, and wildtype optineurin is misfolded and forms inclusions in sporadic ALS patient motor neurons. However it is unknown how optineurin mutation or misfolding leads to ALS. Optineurin acts an adaptor protein connecting the molecular motor myosin VI to secretory vesicles and autophagosomes. Here we demonstrate that ALSlinked mutations p.Q398X and p.E478G disrupt the association of optineurin with myosin VI, leading to an abnormal diffuse cytoplasmic distribution, inhibition of secretory protein trafficking, endoplasmic reticulum (ER) stress and Golgi fragmentation in motor neuron-like NSC-34 cells. We also provide further insight into the role of optineurin as an autophagy receptor. Wildtype optineurin associated with lysosomes and promoted autophagosome fusion to lysosomes in neuronal cells, implying it mediates trafficking of lysosomes during autophagy in association with myosin VI. However, either expression of ALS mutant optineurin or siRNA-mediated knockdown of endogenous optineurin blocked lysosome fusion to autophagosomes, resulting in autophagosome accumulation. Together these results indicate that ALS-linked mutations in optineurin disrupt myosin VI-mediated intracellular trafficking processes. In addition, in control human patient tissues optineurin displayed its normal vesicular localization but in sporadic ALS patient tissues, vesicles were present in a significantly decreased proportion of motor neurons. Optineurin binding to myosin VI was also decreased in tissue lysates from sporadic ALS spinal cords. This study therefore links several previously described pathological mechanisms in ALS, including defects in autophagy, fragmentation of the Golgi, and induction of ER stress, to disruption of optineurin function. These findings also indicate that optineurin-myosin VI dysfunction is a common feature of both sporadic and familial ALS. 
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting motor neurons in the brain, brainstem and spinal cord. Whilst most ALS cases are sporadic, approximately 10% are familial. Mutations in the optineurin gene (OPTN) cause >1% of familial ALS cases and also primary open angle glaucoma, a neurodegenerative eye disorder (1, 2) . ALS is characterized by the accumulation of intracellular ubiquitinated protein inclusions in affected tissues in both familial and sporadic cases. Mutations in the genes encoding TAR DNA binding protein 43 (TDP-43), fused in sarcoma (FUS) and Cu/Zn-superoxide dismutase (SOD1) also cause familial forms of ALS. However, in addition, wildtype (WT) forms of these proteins misfold and are present in inclusions in sporadic ALS motor neurons (3) (4) (5) . Similarly mutant optineurin colocalises with ubiquitinated inclusions in OPTN mutation familial ALS cases (1) , and WT optineurin is present in sporadic ALS motor neuron inclusions (6) . WT optineurin is also present within pathogenic aggregates found in other neurodegenerative disorders, including Alzheimer's, Parkinson's, Huntington's, and Creutzfeld-Jacob diseases and multiple system atrophy (7, 8) .
The etiology of motor neuron dysfunction in ALS remains unclear. However, accumulation of misfolded protein aggregates, induction of endoplasmic reticulum (ER) stress, fragmentation of autophagosomes and then to drive fusion with lysosomes. Autophagosomes were also recently physically and functionally linked to the ER-Golgi compartments, as the formation of autophagosomes occurs from the ER (16) (17) (18) . Disruption to cellular trafficking can trigger ER stress and induce the unfolded protein response (UPR), a homeostatic response to the presence of intracellular misfolded proteins in the ER (19) . ER stress is present in sporadic ALS patients, transgenic rodent models expressing mutant SOD1 and in neuronal cells expressing mutant forms of SOD1, FUS and TDP-43 (10, (20) (21) (22) . We recently demonstrated that cytoplasmic misfolded WT and mutant SOD1 disrupt ER-Golgi transport, and this is associated with ER stress in ALS (12, 13) . These findings raise the possibility that intracellular trafficking disruption is an important upstream event in ALS pathogenesis.
Myosin VI is involved in the intracellular transport of endocytic vesicles, secretory vesicles and autophagosomes (23, 24) . Adaptor proteins link myosin VI to specific cargoes by binding to the myosin VI globular tail/cargo binding domain (25) . Optineurin is one such adaptor protein which co-localises with myosin VI at the Golgi apparatus and plasma membrane (26) . Binding of optineurin triggers dimerization of myosin VI, which allows unconventional processive movement towards the minus end of actin filaments (27) . Optineurin is also an autophagy receptor that directly binds to protein aggregates and microtubule-associated protein 1A/1B-light chain 3 (LC3) (28, 29) . Furthermore, optineurin depletion using siRNA inhibits autophagy (29) and exocytosis (26) . Recently myosin VI was shown to mediate the trafficking of autophagosomes on actin filaments, aiding their fusion with lysosomes (28) . Simultaneous knockdown of optineurin together with other myosin VI associated autophagy adaptors T6BP and NDP52 decreased autophagosome formation and prevented autophagosome-lysosome fusion, suggesting that these three adaptors mediate myosin VI-dependent autophagy trafficking (25) . However the role of these adaptors individually in autophagy has not been determined.
Hence it remains unclear exactly how optineurin, in conjuction with myosin VI, mediates autophagy trafficking, and whether optineurin/myosin VI also associate with lysosomes as well as autophagosomes, to promote autophagosome-lysosome fusion.
The majority of mutations in optineurin that cause ALS are present in the myosin VI binding site (1, 30, 31) . Hence we hypothesized that these mutations disrupt the normal association of optineurin with myosin VI and thus perturb myosin VI-dependent functions in trafficking and
autophagy. Here we demonstrate that in contrast to WT and a glaucoma-causing OPTN mutant (p.E50K, c.148G>A), two ALS-linked OPTN mutants (heterozygous p.E478G, c.1433A>G and homozygous p.Q398X, c.1192C>T) did not bind to myosin VI, form vesicles or co-localise with either autophagosomes or lysosomes in neuronal cells. Expression of the ALS mutants resulted in the accumulation of autophagosomes, suggesting a defect in lysosome fusion, inhibition of secretory protein transport from the Golgi to plasma membrane, and a corresponding induction of ER stress and fragmentation of the neuronal Golgi apparatus. We also demonstrate that WT optineurin associates with lysosomes, thus provding an explanation for previous observations that optineurin-myosin VI mediates autophagosome/lysosome fusion (28) . Moreover, examination of human spinal cord tissues revealed that in sporadic ALS patient motor neurons, optineurin did not bind to myosin VI or form vesicles, implying that loss of optineurin-myosin VI function is present in sporadic ALS. Hence we propose that optineurin and myosin VI defects are present in both familial and sporadic ALS, thus providing new insights into pathogenesis.
RESULTS

ALS mutant optineurin mislocalizes from vesicles in neuronal cells
We expressed four EGFP-tagged optineurin proteins in the NSC-34 motor neuron-like cell line;
WT, ALS mutants E478G and Q398X (1), and a glaucoma mutant, E50K (2) . As expected, the truncation mutant Q398X migrated at a lower apparent molecular weight (~72 kDa) compared to the other proteins (~90 kDa) (Fig S1a) . Immunoblotting revealed increased levels of insoluble optineurin in cells expressing the ALS mutants compared to WT and E50K (p<0.001), indicative of protein misfolding or aggregation (Fig S1a, S1b) . Whilst both WT and E50K formed vesicular structures (defined as punctate structures of less than 3 µm in diameter, Fig S1c) in 70-80% of cells, E478G and Q398X optineurin mutants were expressed in the cytoplasm in a diffuse, nonvesicular manner in most cells (~70%; Fig S1c) , with only <10% of cells bearing vesicles (p<0.0001; S1d), consistent with previous observations (1). Similar findings were obtained when HA-tagged WT and Q398X mutant optineurin were expressed in NSC-34 cells, allowing us to rule out an aberrant effect of EGFP on the cellular distribution of optineurin (Fig S1e, S1f) .
Dissociation of ALS-linked mutant optineurin from myosin VI prevents vesicle formation
We investigated whether the ALS-linked optineurin mutations disturb myosin VI-optineurin function. Firstly, immunocytochemistry of human primary motor neuron cultures revealed that optineurin was present as vesicular structures that co-localised with myosin VI in all cells examined (Fig 1a) , confirming that optineurin-myosin VI function together in human motor neurons. We next examined the interaction between optineurin EGFP-tagged proteins and myosin VI. In transfected NSC-34 cells, WT and E50K optineurin co-localised with vesicular myosin VI, in contrast to E478G or Q398X optineurin mutants, which showed little colocalisation with myosin VI (Fig 1b) . Furthermore, while myosin VI was immunoprecipitated by GFP-Trap in lysates prepared from WT and E50K optineurin expressing cells, little myosin VI was precipitated from E478G or Q398X expressing cells, revealing that the ALS mutants do not bind to myosin VI (Fig 1c) . This finding was confirmed by immunoprecipitation of cell lysates using an anti-myosin VI antibody: little E478G or Q398X co-precipitated with myosin VI in contrast to WT and E50K optineurin (Fig 1d) . Interestingly, endogenous optineurin was precipitated using an anti-myosin VI antibody, from untransfected cells or GFP, WT, E50K optineurin expressing cells, but not from cells expressing E478G or Q398X (Fig 1d) . This result suggests that the optineurin ALS mutants may act in a dominant negative manner to disrupt the interaction of endogenous optineurin with myosin VI. We then examined whether ALS mutant optineurin interacts with endogenous optineurin, to disrupt its interaction with myosin VI. Coprecipitation using GFP-Trap showed that endogenous optineurin co-precipitaed with WT, E50K and E478G ALS mutant optineurin, suggesting that ALS mutant optineurin associates with endogenous optineurin and disrupts its binding with myosin VI (Fig S2a) . Furthermore we performed co-precipitation with GFP-Trap in cells expressing Q398X-HA ALS mutant optineurin with EGFP tagged WT or E50K optineurin. HA tagged Q398X optineurin was precipitated in cells expressing EGFP tagged WT or E50K optineurin using GFP-Trap, suggesting that the ALS mutant optineurin interacts with WT and E50K optineurin (Fig S2b) . In addition the interaction between WT and E50K optineurin with myosin VI was decreased in cells co-expressing Q398X ALS mutant optineurin (Fig S2b) . Hence together these data suggest that ALS mutant optineurin acts in dominant negative manner to induce a loss of association with myosin VI.
We next hypothesized that the loss of binding to myosin VI was responsible for the nonvesicular localization of optineurin observed with the ALS mutants. To investigate this possibility, NSC-34 cells expressing WT optineurin were treated with 2,4,6 triiodophenol (TIP), a pharmacological inhibitor of myosin VI ATPase activity, which should therefore inhibit the functional interaction between myosin VI and optineurin (27, 40) . In TIP-treated cells, significantly fewer optineurin vesicles were formed compared to untreated cells (p<0.05), and optineurin was localized diffusely throughout these cells, similar to ALS mutant expressing cells (Fig 1e, 1f) . Hence a functional association between myosin VI and optineurin is necessary for the formation of optineurin vesicles. This implies that the loss of binding of optineurin to myosin VI in ALS is responsible for the loss of vesicular localization of optineurin.
ALS optineurin mutants inhibit secretory protein trafficking from the Golgi apparatus to the plasma membrane
Since optineurin is an adaptor for myosin VI in exocytosis (26, 41, 42) , we next analysed whether expression of E478G and Q398X ALS optineurin mutants in neuronal cells inhibits the classical secretory pathway. We used a temperature sensitive mutant of vesicular stomatitis viral glycoprotein ts045 (VSVG) as a secretory protein transport marker (43) . VSVG misfolds and is retained within the ER at 40˚C, but upon switching to the permissive temperature of 32˚C, it is transported to the Golgi apparatus by 30 min and to the plasma membrane by 120 min (43) .
Using biotinylation of cell surface proteins, followed by immunoprecipitation with streptavidin beads and immunoblotting, we found that significantly less VSVG (p<0.05) reached the cell surface by 120 min in cells expressing E478G or Q398X compared to WT, E50K or EGFP alone (Fig 2a, 2b) . Similarly, when VSVG-positive vesicles were transported from the Golgi apparatus towards the plasma membrane at 60 min after changing to the permissive temperature, significantly fewer cells showed (p<0.0001) VSVG co-localised with optineurin in E478G or Q398X expressing cells compared to WT and E50K expressing cells (Fig 2c, 2d) . Furthermore live-cell imaging at 60 min demonstrated that WT optineurin, but not E478G or Q398X, comigrates with VSVG vesicles during transit from the Golgi to the plasma membrane (Supplementary video 1, 2, 3) . In contrast, transport of VSVG in the early stages of the secretory pathway, from the ER to Golgi, was not inhibited in cells expressing E478G or Q398X (Fig S3a,   S3b) . Hence, the optineurin ALS mutants specifically inhibit protein transport from the Golgi apparatus to the cell surface during exocytosis.
ALS linked optineurin mutant proteins display decreased co-localisation with autophagosomes and lysosomes
Since we observed decreased binding of the optineurin ALS mutants to myosin VI, we next examined whether the ALS mutations affect the association of optineurin with autophagosomes.
In NSC-34 cells expressing WT or the E50K glaucoma mutant, optineurin co-localised with both myosin VI and LC3-DsRed-positive autophagosomes in 70-80% of cells (Fig 3a, 3b) . However, in cells expressing E478G or Q398X, optineurin co-localised with myosin VI and autophagosomes in significantly fewer cells (~20 % ; Fig 3a, 3b; (Fig 3c) , implying that optineurin links myosin VI to lysosomes, and hence that optineurin/myosin VI could mediate lysosomal trafficking. This was confirmed by staining for myosin VI in NSC-34 cells, co-expressing WT optineurin and LAMP1-RFP, where optineurin and myosin VI were found to co-localize together with lysosomes (Fig 3e) . Live cell imaging studies, similarly showed that vesicles containing WT and E50K optineurin co-migrate with lysosomes stained by the pHsensitive Lysotracker dye (Supplementary video 6, 7) . In contrast, however, in cells expressing E478G or Q398X, optineurin rarely co-localised with LAMP1, indicating that the ALS mutants did not associate with lysosomes (Fig 3c, 3d, p<0 .0001). This was confirmed using live cell imaging studies, in which E478G or Q398X optineurin did not co-migrate with Lysotrackerstained vesicles (Supplementary video 8, 9) . In order to rule out the possibility that optineurin was recruited to lysosomes because of its over-expression in cell culture, we also performed immunocytochemistry of endogenous optineurin and endogenous LAMP2 in human primary motor neurons (Fig. 3f ) and in NSC-34 cells (Fig. 3g ) that were serum-starved to induce autophagy. These studies revealed that endogenous optineurin co-localised with LAMP2-stained lysosomes in all cells examined (Fig. 3f, 3g ), confirming that optineurin associated with lysosomes, unrelated to protein expression level. Together, these data indicate that WT optineurin normally associates with both autophagosomes and lysosomes, but this association is abrogated in ALS.
ALS-linked optineurin mutants inhibit autophagosome-lysosome fusion
The association of optineurin-myosin VI with autophagosomes and lysosomes ( Fig. 3 ) and previous evidence demonstrating that optineurin depletion inhibits autophagy (29, 44) , implies that optineurin/myosin VI mediates the fusion of autophagosomes to lysosomes. We examined this notion by depletion of optineurin using small interfering RNA (siRNA) in NSC-34 cells.
siRNA treatment successfully depleted optineurin expression levels by 84% compared to control siRNA-treated cells (Fig 4a) . After serum starvation to induce autophagy, depletion of optineurin led to increased levels of lipidated LC3-II compared to control siRNA-treated cells, indicating accumulation of autophagosomes. Hence this result indicates that optineurin is required for the clearance of autophagomes (Fig 4a, 4b) . We then examined the fusion of autophagosomes to lysosomes by expressing tandem mCherry-LC3-GFP constructs (45, 46) , under conditions of serum starvation to induce autophagy (Fig 4c) . As the GFP signal is quenched in the acidic/proteolytic conditions of the lysosomal compartment, upon expression of tandem mCherry-LC3-GFP construct, co-localization of both GFP and mCherry fluorescence indicates autophagosomes that has not fused with a lysosome, in contrast, mCherry signal without GFP corresponds to mature autolysosomes in which the autophagosomes have fused lysosomes (46) . (Fig 4e, 4f ). There was no difference in LC3-II in cells expressing WT, E50K, E478G or Q398X in the presence of vacuolar-type H+-ATPase inhibitor bafilomycin A1 (Fig S4) , which blocks the fusion of autophagosomes and lysosomes, indicating that the increase in LC3-II in cells expressing E478G and Q398X mutant optineurin was specifically due to the accumulation of autophagosomes and not increased autophagosome biogenesis (28, 45, 47) . Using fluorescent microscopy, we also observed a significant increase (p<0.0001) in the proportion of E478G or Q398X optineurin-expressing cells containing LC3-DsRed-positive vesicles (>5) compared to WT or E50K expressing cells, indicating autophagosome accumulation in the ALS mutant cells under basal conditions (Fig 4g) . Furthermore, expression of HA-tagged ALS mutant Q398X caused a significant decrease in the proportion of fused autolysosomes per cell, detected by coexpression of tandem mCherry-LC3-GFP construct, under starvation-induced autophagy (p<0.0001) compared to WT or untransfected cells (Fig 4h, 4i ). Together these data indicate that the fusion of autophagosomes to lysosomes was inhibited by expression of optineurin ALS mutants, leading to an accumulation of autophagosomes. Similar findings were obtained in cells depleted of optineurin (Fig 4c, 4d) , thus implying that the ALS mutations cause a loss of function of optineurin in mediating the fusion of autophagosomes with lysosomes.
ALS optineurin mutants cause Golgi fragmentation and induce ER stress
The inhibition of protein transport from the Golgi to plasma membrane and disruption of autophagsome-lysosome trafficking and fusion indicated that the ALS-optineurin mutants trigger dysfunction to the secretory and endocytic compartments. As both ER stress and fragmentation of the Golgi apparatus occur in sporadic and familial ALS (9, 10, 20, 21, 48, 49) and can result from dysfunction to the secretory pathway (12, 19, 50) , we next examined whether these features were present in cells expressing ALS optineurin mutants. Immunoblotting for markers of ER stress, namely inositol requiring kinase 1 (IRE1) and spliced x-box binding protein 1 (Xbp1) (51) , revealed greater activation of ER stress in cells expressing E478G and Q398X (p<0.05) compared to WT or E50K (Fig 5a, 5b) . Similarly, expression of E478G and Q398X caused a significant increase (p<0.001) in nuclear immunoreactivity to C/EBP homologous protein (CHOP), a pro-apoptotic transcription factor activated during the UPR, compared to WT or E50K optineurin expression (Fig 5c, 5d) . We also observed a small but significant up-regulation (p<0.05) of CHOP in cells overexpressing WT and E50K optineurin compared to untransfected or GFP only cells (Fig 5d) , although IRE1 and spliced XBP-1 were not significantly increased (Fig 5b) . Similarly, immunocytochemistry for Golgi marker GM130 demonstrated that fragmented Golgi, indicated by the presence of condensed punctate structures, were present in a greater proportion of NSC-34 cells expressing E478G and Q398X compared to WT and E50K (p<0.05) or GFP and untransfected cells (p<0.0001), where the Golgi retained its characteristic perinuclear location (Fig 5e, 5f) . Consistent with previous studies (52, 53), Golgi fragmentation was also detected in a small but significantly increased proportion of cells expressing WT optineurin and E50K compared to untransfected and GFP expressing cells (Fig 5f) . However, the ALS optineurin mutants induce ER stress and fragmentation of the neuronal Golgi apparatus in NSC-34 neuronal cells to a significantly greater extent than WT or E50K mutant optineurin.
Loss of optineurin association with myosin VI in sporadic ALS
The majority of ALS cases are sporadic without any known genetic mutations. Whilst mutations in optineurin cause a proportion of familial ALS cases (1, 30) , optineurin is also present in motor neuron inclusions in sporadic ALS patients (6) . This suggests that the normal cellular function of WT optineurin might be perturbed in sporadic ALS. Therefore, we next analysed the vesicular localization of optineurin in the motor neurons of ALS patient tissues. For this analysis, large neurons located in the ventral horn regions of spinal cord sections that stained positively using immunohistochemistry for SMI-32 were identified as motor neurons (Fig S5d) .
Immunohistochemistry of lumbar spinal cord sections of sporadic ALS patients and control patients without neurological disease revealed that optineurin-positive vesicles were detected in most (approximately 75%) motor neurons in control tissue, as expected (Fig 6a) . However, significantly fewer motor neurons in sporadic ALS patients contained optineurin-positive vesicular structures (21%, p<0.05). In the ALS patient cells lacking optineurin-positive vesicles, optineurin was either expressed in a diffuse pattern (59%) or recruited to intracellular inclusions (41%) (Fig 6b, 6c) . In contrast, further immunohistochemistry studies revealed that the distribution of myosin VI was unchanged between control and sporadic patient motor neurons, in which it displayed a predominantly vesicular pattern (Fig S5e, S5f) . This implies that loss of vesicular optineurin, but not myosin VI, is present in sporadic ALS patient tissues. We then examined whether the loss of vesicular appearance of optineurin could be due to aggregation of optineurin in sporadic ALS. We sequentially extracted the insoluble protein fraction from human spinal cord lysates using buffers with increasing salt and detergent concentrations and immunoblotted for optineurin. Such an analysis revealed higher amount of sarkosyl insoluble optineurin in sporadic ALS patient spinal cord lysate compared to controls (Fig 6d, 6e ). These results demonstrate that optineurin becomes misfolded in addition to losing its vesicular appearance in sporadic ALS.
The loss of the vesicular localization and misfolding of optineurin in human ALS was similar to the findings obtained from cells expressing ALS mutants E478G and Q398X, which displayed decreased binding to myosin VI (Fig. 1) . Hence, we next examined the association between optineurin and myosin VI in sporadic ALS and control patient spinal cord lysates. Myosin VI co-precipitated using an optineurin antibody in control patient tissue lysates as expected. However, little myosin VI co-precipitated from sporadic ALS patient tissues, suggesting that myosin VI loses its association with optineurin in sporadic disease (Fig 6f, 6g ; additional patients shown in S5a; details of patients shown in Supplementary Table 1 ). To confirm this finding, we coimmunoprecipitated optineurin using an anti-myosin VI antibody. Significantly less optineurin was co-precipitated with the anti-myosin VI antibody from sporadic patient tissues compared to non-neurological controls (Fig S5b, S5c) . Furthermore, to confirm that these ALS patients do not contain ALS mutations, we sequenced DNA extracted from patient tissues for common TDP-43, FUS, and SOD1 mutations and the C9ORF72 repeat expansion. We found a known sporadic TDP-43 mutation, p.G294A, c.880G>C mutation (rs80356721) in patient P3 (54). We did not detect mutations in C9ORF72, TDP-43, FUS or SOD1 in any of the other patients. These patients are therefore most likely to be sporadic cases, given the lack of common diseasecausative mutations and the lack of known family history. Together these data demonstrate that the association between myosin VI and optineurin is disrupted in sporadic ALS patients, implying that the function of optineurin as an adaptor for myosin VI is inhibited in both sporadic and familial ALS.
DISCUSSION
This study describes novel pathogenic mechanisms associated with optineurin in sporadic and familial ALS. We demonstrate that optineurin mutations present in familial ALS inhibit the normal association of optineurin with myosin VI, which prevents the fusion of lysosomes to autophagosomes and inhibits the transport of secretory proteins from the Golgi to the plasma membrane. This results in accumulation of autophagosomes, ER stress and fragmentation of the Golgi apparatus. Furthermore, we also demonstrate that the association between optineurin and myosin VI is inhibited in human sporadic ALS, suggesting that disruption to optineurin function is not confined to rare familial cases. Hence optineurin-myosin VI dysfunction is associated with previously described pathogenic events in ALS and our findings imply that it is a common feature of both familial and sporadic disease.
Protein misfolding and aggregation is a key pathogenic feature of ALS. Autophagy is an important cellular mechanism to eliminate protein aggregates (55, 56) Since the myosin VI binding region of optineurin is located at residues 412-520 (26), both E478G and Q398X mutations are predicted to have decreased myosin VI binding, which may account for the alterations in mutant optineurin localisation. We observed that treatment of cells with a myosin VI inhibitor caused WT optineurin to display a more diffuse, subcellular distribution (Fig 1) , similar to that seen in ALS patient motor neurons (Fig 6) . This implies that interaction of myosin VI with optineurin is important to maintain normal optineurin localization and function. Overall, these findings suggest that a complex mechanism involving both loss of normal optineurin functions and mutation-specific functional changes exists in ALS. Consistent We also observed that ALS optineurin mutants induced Golgi fragmentation and ER stress to a much greater extent than either WT or the glaucoma mutant E50K. This implies that in ALS, dissociation of optineurin from myosin VI disrupts post-Golgi protein trafficking, inducing Golgi fragmentation and ER stress. Similar to this observation, previous studies have shown that inhibition of post-Golgi trafficking leads to accumulation of misfolded proteins in secretory compartments, consequently inducing Golgi fragmentation and ER stress (50, 69, 70) . We also show here that overexpression of both WT and E50K optineurin induces Golgi fragmentation and activates CHOP, albeit to a lesser extent that the ALS mutants, indicating possible pathogenic effects upon over-expression of WT optineurin (71) . Further temporal delineation of the events triggered by ALS mutant optineurin will allow identification of the upstream triggering factors for these changes.
In this study we also provide further insight into the function of WT optineurin as an autophagy receptor. Previously optineurin was identified along with two other adaptor proteins, NDP52 and T6BP, as mediators of myosin VI-dependent autophagosome formation and fusion to lysosomes (28) . However this previous study examined only the simultaneous depletion of all three adaptor proteins using siRNA. In the current study we extend these findings and confirm that in complex with myosin VI, optineurin alone is required for autophagosome/lysosome fusion. We also demonstrate that optineurin and myosin VI associate with lysosomes, and either dissociation of optineurin from myosin VI or knockdown of optineurin blocked the fusion of lysosomes to autophagosomes. However it remains unclear if optineurin physically binds to lysosomes or whether this is mediated by additional binding partners. Hence these findings imply that optineurin links myosin VI to both lysosomes and autophagosomes, leading to their fusion during the final stages of autophagy.
Although previous studies have described tentative links between myosin VI and neurodegeneration, this study is the first to report dysfunction of myosin VI in ALS. Previously, myosin VI was shown to co-localise with tau fibrils in brains of both Alzheimer's disease mouse models and human patients (72) , and myosin VI knockout mice develop astrogliosis in the brain (73) . Our findings suggest that alterations in myosin VI function contribute to several pathways implicated in ALS pathogenesis, including intracellular transport disturbances, ER stress activation and Golgi fragmentation. Further studies of the broad role of myosin VI in ALS and other neurodegenerative disorders are therefore warranted.
In conclusion, this study demonstrates that dissociation of optineurin from myosin VI is associated with disturbances in autophagosome-lysosome fusion, activation of ER stress, Golgi fragmentation and dysfunction in protein secretion. We also demonstrate that optineurin displays altered subcellular distribution in sporadic ALS patient motor neurons, and we identify a decreased interaction between optineurin and myosin VI in sporadic ALS patient spinal cords.
These findings implicate optineurin and myosin VI dysfunction as a possible upstream trigger of several pathogenic mechanisms, in both rare familial mutation carriers and the much more common sporadic ALS cases. These findings suggest new therapeutic avenues for ameliorating motor neuron demise in ALS based on optineurin function. 
MATERIALS AND METHODS
Constructs
Live cell imaging
For live cell imaging, NSC-34 cells were grown on 13 mm coverslips. 48 h after transfection, the cells were shifted to Skyes-Moore chamber (BELLCO) and imaged in Zeiss LSM 510 laser scanning confocal microscope (Zeiss) at 37 ˚C with 5% CO2. The videos were acquired for 60
cycles at an interval of 7 sec. The images were analysed using Imaris software (Bitplane).
Human tissue samples
Human lumbar spinal cord segments (L3-L5) from 10 patients who died of respiratory failure caused by ALS were provided by the MND Research Tissue Bank of Victoria (Supplementary Table 1 Triton X-100) with 1% (v/v) protease inhibitor cocktail (Sigma). After homogenization the samples were centrifuged for 5 min at 15,000 g, and the supernatant was then frozen at -80˚C.
Proteins were quantified using the BCA assay Kit (Pierce). Separation of insoluble fractions from spinal cord sections were performed based on the method described earlier (38) . in PBS and coverslip was mounted with DAKO fluorescent mounting medium.
Sequencing
Genomic DNA was extracted from tissue samples using QIAamp DNA mini Kit (QIAGEN).
Analysis of the C9ORF72 repeat expansion was performed using the method described before (39) . Fragment analysis was performed on an ABI 3730XL DNA Analyzer. All SOD1 exons, TARDBP exon 6, FUS exon 15 and at least 50bp of flanking DNA were amplified using the polymerase chain reaction (PCR, primers available on request). Amplified products were analysed using Big-Dye terminator sequencing on an ABI 3730XL sequencer (Macrogen Inc).
Statistics
Data are presented as mean ± standard error of the mean (SEM) from at least three independent experiments, and were analysed by One-Way ANOVA followed by Tukey's post hoc test using Table 1 ). Data are represented as mean ± SEM; *p<0.05, **p<0.001 using unpaired t test.
Additional patients are shown in Fig. S4 . 
